

VIVIMED LABS LIMITED - STANDALONE
SEGMENT-WISE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE
LISTING AGREEMENT

(INR in lacs)

Particulars	3 Months ended		3 Months ended		12 Months ended
	Unaudited		Unaudited		Audited
	30.06.12	30.06.11	30.06.12	30.06.11	31.03.2012
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)					
a.Speciality Chemicals Business	6,848.02	7,644.10	6,848.02	7,644.10	28,005.44
b.Pharma Business	2,268.04	2,748.85	2,268.04	2,748.85	10,483.29
Total	9,116.06	10,392.95	9,116.06	10,392.95	38,488.73
Less, Inter Segment Revenue					
Net sales / Income from Operations	9,116.06	10,392.95	9,116.06	10,392.95	38,488.73
2.Segment Results (Profit) (+) / Loss (-)before tax and interest from each segment					
a.Speciality Chemicals Business	1,524.61	1,374.33	1,524.61	1,374.33	4,970.17
b.Pharma Business	426.30	562.70	426.30	562.70	2,417.34
Total	1,950.91	1,937.03	1,950.91	1,937.03	7,387.51
Less: 1.Interest	895.01	586.50	895.01	586.50	2,253.49
2.OtherUn-allocable Expenditure net off					
3.Un-allocable Income					
Total Profit Before Tax	1,055.90	1,350.48	1,055.90	1,350.48	5,134.02
3. Capital Employed (Segment Assets - Segment Liabilities)					
a.Speciality Chemicals Business	51365.15	34,957.10	51365.15	34,957.10	30,449.24
b.Pharma Business	6394.00	4,134.70	6394.00	4,134.70	8,588.29
Total	57759.15	39,091.80	57759.15	39,091.80	39,037.53